Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity

Archives of General Psychiatry

Volumn 62, Issue 11, 2005, Pages 1266-1274

  Posey, David J ^a,c   Aman, Michael G ^b   Arnold, L Eugene ^b   Ramadan, Yaser ^b   Witwer, Andrea ^b   Lindsay, Ronald ^b   McDougle, Christopher J ^c   Swiezy, Naomi ^c   Kohn, Arlene ^c   McCracken, James T ^d   Shah, Bhavik ^d   Cronin, Pegeen ^d   McGough, James ^d   Lee, Lisa Sea Yun ^d   Scahill, Lawrence ^e   Martin, Andres ^e   Koenig, Kathleen ^e   Carroll, Deirdre ^e   Young, Christopher ^e   Lancor, Allison ^e   Tierney, Elaine ^f   Ghuman, Jaswinder ^f   Gonzalez, Nilda M ^f   Grados, Marco ^f   Vitiello, Benedetto ^g   Ritz, Louise ^g   Chuang, Shirley ^h   Davies, Mark ^h   Robinson, James ⁱ   McMahon, Don ⁱ   more..

^a RILEY HOSPITAL FOR CHILDREN   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e YALE UNIVERSITY   (United States)

^f KENNEDY KRIEGER INSTITUTE   (United States)

^g NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ABDOMINAL DISEASE; ADOLESCENT; ANXIETY; APPETITE DISORDER; ARTICLE; AUTISM; AUTOMUTILATION; BODY WEIGHT; BRADYCARDIA; CHILD; CLINICAL TRIAL; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EMOTIONAL DISORDER; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERACTIVITY; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; PARENT; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; STOMACH DISEASE; TEACHER; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; COMORBIDITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 27744466024     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.62.11.1266     Document Type: Article

References (27)

1. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA. 2001;285:3093-3099.
2. McDougle CJ, Posey DJ. Autistic and other pervasive developmental disorders. In: Martin A, Scahill L, Charney D, Leckman JF, eds. Pediatric Psychopharmacology: Principles and Practice. New York, NY: Oxford University Press; 2003:563-579.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
4. Volkmar FR, Klin A, Cohen DJ. Diagnosis and classification of autism and related conditions: consensus and issues. In: Cohen DJ, Volkmar FR, eds. Handbook of Autism and Pervasive Developmental Disorders. 2nd ed. New York, NY: John Wiley & Sons Inc; 1997:5-40.
5. Frazier JA, Biederman J, Bellordre CA, Garfield SB, Geller DA, Coffey BJ, Faraone SV. Should the diagnosis of attention deficit/hyperactivity disorder be considered in children with pervasive developmental disorder? J Atten Disord. 2001;4:203-211.
6. Campbell M, Fish B, David R, Shapiro T, Collins P, Koh C. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Child Schizophr. 1972;2:343-358.
7. Campbell M, Small A, Collins P, Friedman E, David R, Genieser N. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Ther Res Clin Exp. 1976;19:70-86.
8. Quintana H, Birmaher B, Stedge D, Lennon S, Freed J, Bridge J, Greenhill L. Use of methylphenidate in treatment of children with autistic disorder. J Autism Dev Disord. 1995;25:283-295.
9. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30:245-255.
10. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14:49-56.
11. Langworthy-Lam KS, Aman MG, Van Bourgondien ME. Patterns and prevalence of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol. 2002;12:311-321.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Dept of Health, Education, and Welfare, National Institute of Mental Health; 1976. NIMH publication 76-338.
14. Swanson JM. School-Based Assessments and Interventions for ADD Students. Irvine, Calif: KC Publishing; 1992.
15. Slosson RL. Slosson Intelligence Test. East Aurora, NY: Slosson Educational Publications; 1983.
16. Sparrow SS, Carrey NJ, Wiggins DM, Millin RP, Hosendocus SN. Vineland Adaptive Behavior Scales. Circle Pines, Minn: American Guidance Service; 1984.
17. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659-686.
18. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485-491.
19. Aman MG, Singh NN. Aberrant Behavior Checklist, Community: Supplementary Manual. East Aurora, NY: Slosson Educational Publications; 1994.
20. Aman MG, Marks ME, Turbott SH, Wilsher CP, Merry SN. Methylphenidate and thioridazine in the treatment of intellectually subaverage children: effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry. 1991;30:816-824.
21. Aman MG, Kern RA, McGhee DE, Arnold LE. Fenfluramine and methylphenidate in children with mental retardation and ADHD: clinical and side effects. J Am Acad Child Adolesc Psychiatry. 1993;32:851-859.
22. Aman MG, Kern RA, Osborne P, Tumuluru R, Rojahn J, del Medico V. Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: clinical effects. Am J Ment Retard. 1997;101:521-534.
23. Di Martino A, Melis G, Cianchetti C, Zuddas A. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol. 2004;14:207-218.
24. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40:180-187.
25. Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn J, Pelham WE, Severe JB, Swanson JM, Vitello B, Wells K. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry. 1996;35:1304-1313.
26. Aman MG, Buican B, Arnold LE. Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of 3 aggregated studies. J Child Adolesc Psychopharmacol. 2003;13:29-40.
27. Aman MG. Stimulant drugs in the developmental disabilities revisited. J Dev Phys Disabil. 1996;8:347-365.